US4268526A - Cosmetic cream formulation - Google Patents
Cosmetic cream formulation Download PDFInfo
- Publication number
- US4268526A US4268526A US06/179,626 US17962680A US4268526A US 4268526 A US4268526 A US 4268526A US 17962680 A US17962680 A US 17962680A US 4268526 A US4268526 A US 4268526A
- Authority
- US
- United States
- Prior art keywords
- skin
- regime
- phase
- cream formulation
- hydroxybenzoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000009472 formulation Methods 0.000 title claims abstract description 12
- 239000008278 cosmetic cream Substances 0.000 title 1
- 239000002884 skin cream Substances 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 claims description 4
- UKHVLWKBNNSRRR-ODZAUARKSA-M dowicil 200 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C\C=C/Cl)C3 UKHVLWKBNNSRRR-ODZAUARKSA-M 0.000 claims description 4
- 229940059904 light mineral oil Drugs 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- KJYGRYJZFWOECQ-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-(16-methylheptadecanoyloxy)propoxy]propoxy]propyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCC(C)C KJYGRYJZFWOECQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical group O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000007765 cera alba Substances 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 229920005638 polyethylene monopolymer Polymers 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 230000003822 cell turnover Effects 0.000 abstract description 8
- 230000001256 tonic effect Effects 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 239000006210 lotion Substances 0.000 abstract description 6
- 206010040880 Skin irritation Diseases 0.000 abstract description 5
- 230000036556 skin irritation Effects 0.000 abstract description 5
- 231100000475 skin irritation Toxicity 0.000 abstract description 5
- 210000001339 epidermal cell Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 8
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- -1 Polyethylene Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- PCHILFRTAHDLEQ-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid;methyl 4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1.CC1=CC(O)=CC=C1C(O)=O PCHILFRTAHDLEQ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- MBXVIRZWSHICAV-UHFFFAOYSA-N Glycerol triundecanoate Chemical compound CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCC)COC(=O)CCCCCCCCCC MBXVIRZWSHICAV-UHFFFAOYSA-N 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PASCYLAFGHJSHW-UHFFFAOYSA-N ethyl 2-[(4-methoxyphenyl)methyl]-3-(methylamino)propanoate Chemical compound CCOC(=O)C(CNC)CC1=CC=C(OC)C=C1 PASCYLAFGHJSHW-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- This invention relates to one component for use in a novel cell renewal cosmetic regime, which regime increases the rate of cell turnover without skin irritation.
- Acceleration of natural cell renewal or turnover speeds the replacement of dead cells by new ones in the outer epidermal layer or stratum corneum, thereby giving the skin a younger-looking appearance.
- the newer cells are moist and fresh, replacing the old, dry cells on the surface.
- a skin cream formulation which is one of four components for use in a cosmetic regime.
- the regime's use increases epidermal cell turnover without skin irritation.
- the other three components for use in the regime are: a cleanser, a lotion, and a tonic.
- a skin cream formulation which is one of four components for use in a cosmetic regime.
- the use of the regime increases cell turnover without causing skin irritation.
- the regime consists of the application to the skin of a cleanser, a cream, a lotion, and a tonic.
- Each of the three other components is a separate invention; the cleanser is claimed in application Ser. No. 179,628, filed of even date herewith, the lotion is claimed in application Ser. No. 179,629, also filed of even date herewith, and the tonic is claimed in application Ser. No. 179,625, filed of even date herewith.
- the use of the four components in a regime to increase cell turnover is claimed in application Ser. No. 179,627, filed of even date herewith.
- the preferred regime usually begins in the morning with the use of the tonic, followed by the lotion. Later, usually at night, the cleanser is used, and then the tonic and cream are applied.
- the order and the timing of the use of the four products can be varied to suit individual needs.
- the cleanser also can be used in the morning. Some effect will be obtained even if all the compositions are not used or if there is a delay between usage.
- the cream formulation consists essentially of, in percent by weight:
- the individual ingredients used in the formulation should be of a quality or purity (such as U.S.P. or N.F.) suitable for cosmetic use.
- the formulation of this invention is prepared by mixing the ingredients according to conventional methods.
- the preparation of this formulation is described in the following example.
- the example is illustrative of the formulation embraced by the invention, but is not to be construed as limiting the invention.
- Phase A The light mineral oil of Phase A is heated to about 90°-95° C. and then the polyethylene is added while mixing with a Lightnin' mixer. The mixing is continued until Phase A becomes a clear solution.
- the ingredients of Phase B are added to a jacketed tank that is equipped with a homomixer and a side-sweep (Ross). Phase B is heated to about 90°-95° C. and mixed thoroughly. Phase A is added to Phase B and then mixed thoroughly with the homomixer.
- Phase AB While Phase AB is being mixed with the homomixer, the Bentone of Phase C is slowly sprinkled into Phase AB. Mixing is continued until the Bentone is completely wetted and a homogeneous mass is acquired. The temperature is maintained at 90°-95° C.
- Phase D The ingredients of Phase D are added to a container equipped with a Lightnin' mixer. The container is then heated to about 90°-95° C. and Phase D is mixed until the powder ingredients are dissolved. Phase D is added to Phase ABC and mixed with the homomixer and side-sweep. The product is homomixed until it becomes homogeneous and has a bright white shine. Homomixing is stopped when the product has cooled to 50° C., but side-sweeping continues. The product is then cooled, but must not be shock cooled.
- Phase E is prepared separately by dissolving the Dowicil 200 in the deionized water.
- Phase ABCD is cooled to about 40°-45° C. and Phase E is added.
- the product is mixed thoroughly with the side-sweep.
- Phase F is added, keeping the mixture at about 40°-45° C. and mixing completely.
- the product is then discharged into suitable stainless steel storage containers.
- the rate of skin cell turnover is increased without skin irritation.
- the rate of skin cell turnover is frequently reported as transit time.
- Transit time is defined as the time required for a newly formed stratum corneum cell to rise up through the stratum corneum and finally slough off. Therefore, the less transit time required, the better the appearance of the skin, because younger cells are on its surface.
- the test for measuring transit time is described by L. H. Jansen, et al., "Improved Fluorescence Staining Technique for Estimating Turnover of the Human Stratum Corneum", British Journal of Dermatology, 1974, 90, 9-12.
- the transit or replacement time of the human stratum corneum is determined by measuring the number of days required for a fluorescent marker, dansyl chloride, to disappear after application to the skin.
- the dansyl chloride only stains the stratum corneum (outer cell layer) and the shedding of the stratum corneum is signified by the disappearance of the dansyl chloride.
- the transit time of the present regime is measured and compared with the transit time of several commercially available, skin-care cosmetic products, identified as products A to E in Table I.
- Dansyl chloride is applied to both upper inner arms of each subject, after two weeks of pretreatment with the product. Then one arm is treated daily with the particular product, while the other arm is untreated. The number of days required for the dansyl chloride to disappear from each arm is then recorded. The results for the treated arms are averaged for the particular product and compared to the average for the untreated arms. The results are shown in Table I. The larger the difference between the control and treated times, the more effective is the product.
- the test was run using women from young (19-29 years) and middle (31-58 years) age groups for products A-E and the regime.
- the present regime consists of using all four components in the following order: the cleanser and tonic were used in the morning, followed by the lotion; later, at night, the cleanser was used and then the tonic and cream were applied.
Abstract
A skin cream formulation, which is one of four components used in a cosmetic regime, is disclosed. Applying the regime to the skin increases epidermal cell turnover without skin irritation. The other three components used in the regime are a cleanser, a lotion, and a tonic.
Description
This invention relates to one component for use in a novel cell renewal cosmetic regime, which regime increases the rate of cell turnover without skin irritation.
In the natural renewing cycle of skin, cells are constantly being born, rising through the epidermal layers to the surface and falling off. A young skin renews its surface layers every two to three weeks. A mature skin can take twice as long. And the longer this process takes, the more cells develop areas of weakness that cause a faster loss of natural moisture and the dry lifeless appearance that's found in older looking skin.
Acceleration of natural cell renewal or turnover speeds the replacement of dead cells by new ones in the outer epidermal layer or stratum corneum, thereby giving the skin a younger-looking appearance. The newer cells are moist and fresh, replacing the old, dry cells on the surface.
Although irritation of the skin will increase the sloughing off of dead stratum corneum cells, such irritation is undesirable because of the damage to the skin. It is, therefore, desirable to increase cell turnover without irritation.
It is, therefore, an object of the present invention to provide a skin cream formulation, which is one of four components for use in a cosmetic regime. The regime's use increases epidermal cell turnover without skin irritation. The other three components for use in the regime are: a cleanser, a lotion, and a tonic.
In accordance with this invention there is provided a skin cream formulation, which is one of four components for use in a cosmetic regime. The use of the regime increases cell turnover without causing skin irritation. The regime consists of the application to the skin of a cleanser, a cream, a lotion, and a tonic. Each of the three other components is a separate invention; the cleanser is claimed in application Ser. No. 179,628, filed of even date herewith, the lotion is claimed in application Ser. No. 179,629, also filed of even date herewith, and the tonic is claimed in application Ser. No. 179,625, filed of even date herewith. The use of the four components in a regime to increase cell turnover is claimed in application Ser. No. 179,627, filed of even date herewith.
The preferred regime usually begins in the morning with the use of the tonic, followed by the lotion. Later, usually at night, the cleanser is used, and then the tonic and cream are applied. However, the order and the timing of the use of the four products can be varied to suit individual needs. For example, the cleanser also can be used in the morning. Some effect will be obtained even if all the compositions are not used or if there is a delay between usage.
The cream formulation consists essentially of, in percent by weight:
______________________________________
Ingredients Percent
______________________________________
light mineral oil 4.45
polyethylene homopolymer (1500 m. wt.,
density 0.91 g/cc) 2.50
undecanoic triglyceride
2.00
squalane 5.00
distilled lanolin alcohol
0.55
white beeswax 1.00
polydimethyl cyclosiloxane
9.00
triglyceryl diisostearate
4.00
isopropyl myristate 5.00
propyl p-hydroxybenzoate
0.10
quaternary bentonite 0.40
deionized water 59.00
methyl p-hydroxybenzoate
0.20
70% sorbitol solution 5.00
imidazolidinyl urea 0.30
urea 0.50
glyoxyldiureide 0.20
DL-pantothenyl alcohol 0.50
cis-1-(3-chloroallyl)-3,5,7-triaza-1-
azoniaadamantane chloride
0.10
fragrance 0.20
______________________________________
In general, the individual ingredients used in the formulation should be of a quality or purity (such as U.S.P. or N.F.) suitable for cosmetic use.
The formulation of this invention is prepared by mixing the ingredients according to conventional methods. The preparation of this formulation is described in the following example. The example is illustrative of the formulation embraced by the invention, but is not to be construed as limiting the invention.
Formulation:
______________________________________
Percent
Phase Ingredient by Weight
______________________________________
A light mineral oil 4.45
Polyethylene 617 (Allied Chemical,
polyethylene homopolymer, 1500
m. wt., density 0.91 g/cc,
softening pt. 102° C., viscosity
at 140° C. 145 cps)
2.50
B glyceryl triundecanoate
(undecanoic triglyceride)
2.00
Robane (Robeco, squalane)
5.00
Super Hartolan (Croda, distilled
lanolin alcohol) 0.55
white beeswax 1.00
Silicone Fluid 344 (Dow Corning,
polydimethyl cyclosiloxane)
9.00
triglyceryl diisostearate (poly-
glyceryl-3-diisostearate)
4.00
isopropyl myristate 5.00
propylparaben(propyl p-hydroxy-
benzoate) 0.10
C Bentone No. 38 (NL Industries,
quaternary bentonite) 0.40
D deionized water 58.00
methylparaben (methyl p-hydroxy
benzoate) 0.20
sorbitol solution 70% (U.S.P. Sorbo)
5.00
imidazolidinyl urea 0.30
urea 0.50
Allantoin (Sutton and Schuylkill,
glyoxyldiureide) 0.20
dL-Panthenol (DL-pantothenyl alcohol)
0.50
E Dowicil 200 (Dow Chemical, cis isomer
of 1-(3-chloroallyl)-3,5,7-triaza-
1-azoniaadamantane chloride)
0.10
deionized water 1.00
F Essence 66.001 (Firmenich, fragrance)
0.20
______________________________________
Procedure:
The light mineral oil of Phase A is heated to about 90°-95° C. and then the polyethylene is added while mixing with a Lightnin' mixer. The mixing is continued until Phase A becomes a clear solution. The ingredients of Phase B are added to a jacketed tank that is equipped with a homomixer and a side-sweep (Ross). Phase B is heated to about 90°-95° C. and mixed thoroughly. Phase A is added to Phase B and then mixed thoroughly with the homomixer.
While Phase AB is being mixed with the homomixer, the Bentone of Phase C is slowly sprinkled into Phase AB. Mixing is continued until the Bentone is completely wetted and a homogeneous mass is acquired. The temperature is maintained at 90°-95° C.
The ingredients of Phase D are added to a container equipped with a Lightnin' mixer. The container is then heated to about 90°-95° C. and Phase D is mixed until the powder ingredients are dissolved. Phase D is added to Phase ABC and mixed with the homomixer and side-sweep. The product is homomixed until it becomes homogeneous and has a bright white shine. Homomixing is stopped when the product has cooled to 50° C., but side-sweeping continues. The product is then cooled, but must not be shock cooled.
Phase E is prepared separately by dissolving the Dowicil 200 in the deionized water. Phase ABCD is cooled to about 40°-45° C. and Phase E is added. The product is mixed thoroughly with the side-sweep. Phase F is added, keeping the mixture at about 40°-45° C. and mixing completely. The product is then discharged into suitable stainless steel storage containers.
When the above-described formulations are used in accordance with the method of this invention, the rate of skin cell turnover is increased without skin irritation. The rate of skin cell turnover is frequently reported as transit time. Transit time is defined as the time required for a newly formed stratum corneum cell to rise up through the stratum corneum and finally slough off. Therefore, the less transit time required, the better the appearance of the skin, because younger cells are on its surface.
The test for measuring transit time is described by L. H. Jansen, et al., "Improved Fluorescence Staining Technique for Estimating Turnover of the Human Stratum Corneum", British Journal of Dermatology, 1974, 90, 9-12. The transit or replacement time of the human stratum corneum is determined by measuring the number of days required for a fluorescent marker, dansyl chloride, to disappear after application to the skin. The dansyl chloride only stains the stratum corneum (outer cell layer) and the shedding of the stratum corneum is signified by the disappearance of the dansyl chloride.
Using the Jansen procedure, the transit time of the present regime is measured and compared with the transit time of several commercially available, skin-care cosmetic products, identified as products A to E in Table I. Dansyl chloride is applied to both upper inner arms of each subject, after two weeks of pretreatment with the product. Then one arm is treated daily with the particular product, while the other arm is untreated. The number of days required for the dansyl chloride to disappear from each arm is then recorded. The results for the treated arms are averaged for the particular product and compared to the average for the untreated arms. The results are shown in Table I. The larger the difference between the control and treated times, the more effective is the product.
The test was run using women from young (19-29 years) and middle (31-58 years) age groups for products A-E and the regime.
The present regime consists of using all four components in the following order: the cleanser and tonic were used in the morning, followed by the lotion; later, at night, the cleanser was used and then the tonic and cream were applied.
TABLE I
______________________________________
Mean Transit Time.sup.a
Treated
Number with Control Dif-
Product of Subjects
Product (untreated)
ference
______________________________________
A 11 16.1 17.0 0.9
B 11 15.9 17.3 1.4
C 10 14.1 15.3 1.2
D 10 13.5 16.0 2.5
E 10 18.2 22.1 3.9
Regime
(young age group)
8 13.75 20.63 6.88
Regime
(middle age group)
12 15.67 22.08 6.41
______________________________________
.sup.a in days
Claims (1)
1. A skin cream formulation consisting essentially of, in percent by weight:
______________________________________
Ingredients Percent
______________________________________
light mineral oil 4.45
polyethylene homopolymer (1500 m. wt.,
density 0.91 g/cc) 2.50
undecanoic triglyceride
2.00
squalane 5.00
distilled lanolin alcohol
0.55
white beeswax 1.00
polydimethyl cyclosiloxane
9.00
triglyceryl diisostearate
4.00
isopropyl myristate 5.00
propyl p-hydroxybenzoate
0.10
quaternary bentonite 0.40
deionized water 59.00
methyl p-hydroxybenzoate
0.20
70% sorbitol solution 5.00
imidazolidinyl urea 0.30
urea 0.50
glyoxyldiureide 0.20
DL-pantothenyl alcohol 0.50
cis-1-(3-chloroallyl)-3,5,7-triaza-1-
azoniaadamantane chloride
0.10
fragrance 0.20
______________________________________
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/179,626 US4268526A (en) | 1980-08-20 | 1980-08-20 | Cosmetic cream formulation |
| CA000374488A CA1148472A (en) | 1980-08-20 | 1981-04-02 | Cosmetic cream formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/179,626 US4268526A (en) | 1980-08-20 | 1980-08-20 | Cosmetic cream formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4268526A true US4268526A (en) | 1981-05-19 |
Family
ID=22657330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/179,626 Expired - Lifetime US4268526A (en) | 1980-08-20 | 1980-08-20 | Cosmetic cream formulation |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4268526A (en) |
| CA (1) | CA1148472A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4368187A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Sensitive-skin care regime |
| US4372944A (en) * | 1981-08-03 | 1983-02-08 | Eli Lilly And Company | Cosmetic cream formulation |
| EP0095615A2 (en) * | 1982-05-17 | 1983-12-07 | S.C. Johnson & Son, Inc. | Skin conditioning composition |
| US4595586A (en) * | 1985-08-30 | 1986-06-17 | Eli Lilly And Company | Moisturizing lotion |
| US4690821A (en) * | 1984-02-10 | 1987-09-01 | Creative Products Resource Associates, Ltd. | Towel for skin moisturizing and drying |
| US4880563A (en) * | 1985-08-01 | 1989-11-14 | Deutsche Ici Gmbh | Composition for personal care product comprising alkoxylated fatty alcohol and polysiloxane |
| US4900550A (en) * | 1987-08-19 | 1990-02-13 | Amy Allene Cosmetiques, Inc. | Skin care cosmetic regime |
| US20040191330A1 (en) * | 2003-03-31 | 2004-09-30 | Keefe Candace R. | Daily skin care regimen |
| US6844014B1 (en) | 2002-07-22 | 2005-01-18 | Stephen Rafkin | Herbal healing lotion for veterinary use |
| DE10360503A1 (en) * | 2003-12-22 | 2005-07-14 | Sanguibiotech Gmbh | Combination set and method for the bio-regenerative treatment of skin |
| US7135442B2 (en) * | 2001-01-12 | 2006-11-14 | Novartis Ag | Lens care product containing dexpanthenol |
| US7306810B1 (en) | 2002-11-25 | 2007-12-11 | Piedmont Cosmeceuticals, Inc. | Skin cream |
| WO2012006107A2 (en) | 2010-06-28 | 2012-01-12 | Stemtide, Inc. | Skin care compositions |
| WO2013091894A2 (en) | 2011-12-21 | 2013-06-27 | Flavin Dana | Topical compositions |
-
1980
- 1980-08-20 US US06/179,626 patent/US4268526A/en not_active Expired - Lifetime
-
1981
- 1981-04-02 CA CA000374488A patent/CA1148472A/en not_active Expired
Non-Patent Citations (2)
| Title |
|---|
| A-C Polyethylene Bulletin (5011-20-1) Jun. 21, 1977. _ * |
| A-C Polyethylene Bulletin (5011-22-4) Jul. 14, 1977. _ * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4368187A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Sensitive-skin care regime |
| US4372944A (en) * | 1981-08-03 | 1983-02-08 | Eli Lilly And Company | Cosmetic cream formulation |
| EP0095615A2 (en) * | 1982-05-17 | 1983-12-07 | S.C. Johnson & Son, Inc. | Skin conditioning composition |
| EP0095615A3 (en) * | 1982-05-17 | 1984-09-26 | S.C. Johnson & Son, Inc. | Skin conditioning composition |
| US4478853A (en) * | 1982-05-17 | 1984-10-23 | S. C. Johnson & Son, Inc. | Skin conditioning composition |
| US4690821A (en) * | 1984-02-10 | 1987-09-01 | Creative Products Resource Associates, Ltd. | Towel for skin moisturizing and drying |
| US4880563A (en) * | 1985-08-01 | 1989-11-14 | Deutsche Ici Gmbh | Composition for personal care product comprising alkoxylated fatty alcohol and polysiloxane |
| US4595586A (en) * | 1985-08-30 | 1986-06-17 | Eli Lilly And Company | Moisturizing lotion |
| US4900550A (en) * | 1987-08-19 | 1990-02-13 | Amy Allene Cosmetiques, Inc. | Skin care cosmetic regime |
| US7135442B2 (en) * | 2001-01-12 | 2006-11-14 | Novartis Ag | Lens care product containing dexpanthenol |
| US6844014B1 (en) | 2002-07-22 | 2005-01-18 | Stephen Rafkin | Herbal healing lotion for veterinary use |
| US7306810B1 (en) | 2002-11-25 | 2007-12-11 | Piedmont Cosmeceuticals, Inc. | Skin cream |
| US20040191330A1 (en) * | 2003-03-31 | 2004-09-30 | Keefe Candace R. | Daily skin care regimen |
| DE10360503A1 (en) * | 2003-12-22 | 2005-07-14 | Sanguibiotech Gmbh | Combination set and method for the bio-regenerative treatment of skin |
| WO2012006107A2 (en) | 2010-06-28 | 2012-01-12 | Stemtide, Inc. | Skin care compositions |
| WO2013091894A2 (en) | 2011-12-21 | 2013-06-27 | Flavin Dana | Topical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1148472A (en) | 1983-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4272544A (en) | Skin cell renewal regime | |
| US4268526A (en) | Cosmetic cream formulation | |
| US6461623B2 (en) | Cosmetic composition | |
| EP0461593B1 (en) | Hair cleansing composition | |
| EP0586929B1 (en) | Hair treatment composition and process | |
| EP0407089B1 (en) | Cosmetic composition | |
| US4278570A (en) | Cosmetic cleanser formulation | |
| CA1300511C (en) | Cosmetic composition containing a hair growth promoter | |
| US5525344A (en) | Clear cold cream cosmetic compositions | |
| US5660818A (en) | Bioflavonoids as agents for protecting the physical and/or cosmetic properties of keratinous superficial body growths | |
| KR20040043194A (en) | Cosmetic composition with skin tightening effect | |
| JP2000309521A (en) | Skin lotion | |
| US4268502A (en) | Cosmetic tonic formulation | |
| KR100540616B1 (en) | Foaming cosmetic composition, uses for cleansing or make-up removal | |
| JP2017095368A (en) | Skin cleanser | |
| KR100849100B1 (en) | Gel type cosmetic composition for using skin keratin removing and manufacturing method thereof | |
| NO842674L (en) | COSMETIC PREPARATION | |
| JP3540165B2 (en) | Gel cleansing cosmetic | |
| US4272519A (en) | Cosmetic lotion formulation | |
| US5086040A (en) | Novel dermatological composition and method | |
| JPS6075405A (en) | Powdery solid cosmetic | |
| CA2016351C (en) | Cosmetic composition | |
| CA1160957A (en) | Cosmetic cream formulation | |
| WO1985004803A1 (en) | Hyaluronic acid/hyaluronate based fragrance products | |
| JP2002255827A (en) | Skin care preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| AS | Assignment |
Owner name: ELI LILLY AND COMPANY, 307 E. MCCARTY ST., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:VARGAS OVIDIO;HERROLD ANNE M.;REEL/FRAME:003828/0160 Effective date: 19800818 |
|
| AS | Assignment |
Owner name: ELIZABETH ARDEN, INC., PARK AVENUE PLAZA, 55 EAST Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ELI LILLY AND COMPANY;REEL/FRAME:004824/0722 Effective date: 19871222 Owner name: ELIZABETH ARDEN, INC., A INDIANA CORP.,NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELI LILLY AND COMPANY;REEL/FRAME:004824/0722 Effective date: 19871222 |
|
| AS | Assignment |
Owner name: MANUFACTURERS HANOVER TRUST COMPANY Free format text: SECURITY INTEREST;ASSIGNOR:ELIZABETH ARDEN, INC.;REEL/FRAME:004857/0743 Effective date: 19871222 |
|
| AS | Assignment |
Owner name: ELIZABETH ARDEN COMPANY, A DIVISION OF LEVER BROTH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ELIZABETH ARDEN, INC.;REEL/FRAME:005156/0410 Effective date: 19890803 |
|
| AS | Assignment |
Owner name: ELIZABETH ARDEN COMPANY, DIVISION OF CONOPCO, INC. Free format text: SECRETARY'S CERTIFICATE - BENEFICIAL INTEREST AND OWNERSHIP;ASSIGNOR:ELIZABETH ARDEN COMPANY;REEL/FRAME:006335/0637 Effective date: 19921116 |